TY - JOUR
T1 - Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS)
T2 - A theoretical and evidence–based approach. Part II: The clinical application of nonpharmacologic care for NAS/NOWS
AU - Velez, Martha L.
AU - Jordan, Chloe
AU - Jansson, Lauren M.
N1 - Funding Information:
The authors have no financial interests or relationships that pose a potential conflict of interest with this article. The preparation of this manuscript was supported by a grant from the National Institute on Drug Abuse of the National Institutes of Health under award number RO1DA041367 (Jansson). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, Johns Hopkins University School of Medicine, or McLean Hospital/Harvard Medical School.
Funding Information:
The authors have no financial interests or relationships that pose a potential conflict of interest with this article. The preparation of this manuscript was supported by a grant from the National Institute on Drug Abuse of the National Institutes of Health under award number RO1DA041367 (Jansson). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health , Johns Hopkins University School of Medicine , or McLean Hospital/Harvard Medical School .
Publisher Copyright:
© 2021
PY - 2021/11/1
Y1 - 2021/11/1
N2 - There has been increasing emphasis on the importance of the development of self-regulatory capacities of the individual as the cornerstone of development. The caregivers' abilities to manage their own attention, emotions, physiology and behaviors influence the development of the child's self-regulatory and interactive capacities, and thereby their overall development. Newborns prenatally exposed to psychoactive substances and/or to other prenatal stressors such as maternal poor nutrition, increased maternal stress, trauma, difficult and/or impoverished environments, in tandem with genetic predispositions, can result in alterations to their neurodevelopment that predispose them to self-regulatory problems that can be expressed at any stage of life. The care of infants with Neonatal Abstinence Syndrome (NAS)/Neonatal Opioid Withdrawal Syndrome (NOWS) and their mother/caregiver is a window of opportunity to assess the regulatory and co-regulatory capacities of both, and to provide holistic interventions with the goal of empowering the mother/caregiver in their own self-knowledge/self-regulation capacities and their crucial role in promoting the healthy development of their children. Non-pharmacologic care for the infant with NAS/NOWS is the first line of treatment and of paramount importance. Yet, current approaches are based on a limited scope of infant functioning, and the scoring systems in current use do not result in individualized and specific non-pharmacologic care of the infant, which can result in excessive or insufficient medication and a lack of caregiver appreciation for the infant's strengths, difficulties and early development. The interventions described here are based on the infant's signs of dysregulation in four neurobehavioral subsystems that can be dysregulated by NAS/NOWS, the infant's adaptive or maladaptive responses to return to a regulated functioning, and the co-regulatory behaviors of the infant and the mother/caregiver. In Part I of this two-part series on re-conceptualizing non-pharmacologic care for NAS/NOWS we laid the foundation for a new treatment approach, one grounded in developmental theory and evidence-based observations of infant and interpersonal neurobiology. Here, in Part II, we outline actionable, individually tailored evaluations and approaches to non-pharmacologic NAS/NOWS treatment based on strategies to support the regulatory capacities and development of 4 key domains: 1) autonomic; 2) motor/tone; 3) sleep/awake state control; and 4) sensory modulation subsystems.
AB - There has been increasing emphasis on the importance of the development of self-regulatory capacities of the individual as the cornerstone of development. The caregivers' abilities to manage their own attention, emotions, physiology and behaviors influence the development of the child's self-regulatory and interactive capacities, and thereby their overall development. Newborns prenatally exposed to psychoactive substances and/or to other prenatal stressors such as maternal poor nutrition, increased maternal stress, trauma, difficult and/or impoverished environments, in tandem with genetic predispositions, can result in alterations to their neurodevelopment that predispose them to self-regulatory problems that can be expressed at any stage of life. The care of infants with Neonatal Abstinence Syndrome (NAS)/Neonatal Opioid Withdrawal Syndrome (NOWS) and their mother/caregiver is a window of opportunity to assess the regulatory and co-regulatory capacities of both, and to provide holistic interventions with the goal of empowering the mother/caregiver in their own self-knowledge/self-regulation capacities and their crucial role in promoting the healthy development of their children. Non-pharmacologic care for the infant with NAS/NOWS is the first line of treatment and of paramount importance. Yet, current approaches are based on a limited scope of infant functioning, and the scoring systems in current use do not result in individualized and specific non-pharmacologic care of the infant, which can result in excessive or insufficient medication and a lack of caregiver appreciation for the infant's strengths, difficulties and early development. The interventions described here are based on the infant's signs of dysregulation in four neurobehavioral subsystems that can be dysregulated by NAS/NOWS, the infant's adaptive or maladaptive responses to return to a regulated functioning, and the co-regulatory behaviors of the infant and the mother/caregiver. In Part I of this two-part series on re-conceptualizing non-pharmacologic care for NAS/NOWS we laid the foundation for a new treatment approach, one grounded in developmental theory and evidence-based observations of infant and interpersonal neurobiology. Here, in Part II, we outline actionable, individually tailored evaluations and approaches to non-pharmacologic NAS/NOWS treatment based on strategies to support the regulatory capacities and development of 4 key domains: 1) autonomic; 2) motor/tone; 3) sleep/awake state control; and 4) sensory modulation subsystems.
KW - Co-regulation
KW - Development
KW - Dyad
KW - Maternal opioid use disorder
KW - Neonatal abstinence syndrome
KW - Neonatal opioid withdrawal syndrome
KW - Neurobehavior
KW - Non-pharmacologic care
KW - Opioids
UR - http://www.scopus.com/inward/record.url?scp=85117121341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117121341&partnerID=8YFLogxK
U2 - 10.1016/j.ntt.2021.107032
DO - 10.1016/j.ntt.2021.107032
M3 - Article
C2 - 34600100
AN - SCOPUS:85117121341
SN - 0892-0362
VL - 88
JO - Neurobehavioral toxicology
JF - Neurobehavioral toxicology
M1 - 107032
ER -